Previous 10 | Next 10 |
– In preclinical studies, XL092 demonstrated robust target and tumor growth inhibition – – Clinical pharmacokinetic (PK) data suggest a significantly shorter half-life than cabozantinib – – Phase 1 evaluation of XL092 in...
Shares of Exelixis (NASDAQ: EXEL) rose 10% in September, according to data from S&P Global Market Intelligence , after the company announced a series of positive developments throughout the month related to various cancer therapies. Exelixis is already on track to genera...
Exelixis stock has been up and down on news of progress of Checkmate 9-ER trial evaluating lead candidate Cabometyx and Opdivo in RCC. The combo will likely win approval but this may not necessarily lead to blockbuster sales for the company. Meanwhile, current sales volumes are fl...
Exelixis reports data from COSMIC-021 trial of Cabozantinib. Agios reports final overall survival data for Tibsovo. Illumina boosts its oncology portfolio, announces to acquire GRAIL. For further details see: Exelixis Cabozantinib Data, And Other News: The Good, Bad And ...
The CheckMate-9ER of Cabometyx and Opdivo was successful, but not definitively superior to the established combo of Pfizer's Inlyta and Merck's Keytruda. The Cabo-Opdivo combo appeared to work better in sicker patients, and the better tolerability (notably lower discontinuations) coul...
– Cabozantinib in combination with atezolizumab demonstrated promising preliminary efficacy and a favorable safety profile in cohorts of patients with clear cell and non-clear cell renal cell carcinoma – – Data presented during the European Society f...
Bristol Myers Squibb (BMY) and Exelixis (EXEL) announce results from the pivotal Phase 3 CheckMate -9ER trial evaluating patients with previously untreated advanced or metastatic renal cell carcinoma ((RCC)).A total of 651 patients were randomized to Opdivo (nivolumab) plus CABOMETYX (ca...
Opdivo in combination with CABOMETYX showed superior overall survival and doubled median progression-free survival and objective response rate with a favorable safety profile vs. sunitinib Efficacy benefits were observed across key patient subgroups, including all International M...
Exelixis, Inc. (EXEL) Cantor 2020 Global Virtual Healthcare Conference September 16, 2020, 04:40 PM ET Company Participants Michael Morrissey - CEO, President Conference Call Participants Alethia Young - Cantor Presentation Operator Alethia Young Hey, everybody. I...
Exelixis, Inc. (EXEL) BofA Global Healthcare Conference September 16, 2020, 12:35 pm ET Executives Mike Morrissey - President, Chief Executive Officer Analysts Jason Gerberry - Bank of America Merrill Lynch Presentation Jason Gerberry All right. Good afternoon, good e...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...